Zidovudine Articles
EUROPE STOCK COMMENT
7 September 1992
USE OF GROWTH FACTORS IN AIDS MANAGEMENT
7 September 1992
MORE GENERIC RETROVIR IN CANADA
3 August 1992
NEW DRUGS HIGHLIGHTED AT AIDS CONFERENCE
3 August 1992
Europe: Stock comment
6 July 1992
GENERIC RETROVIR FROM BRAZIL
6 July 1992
WELLCOME SHARES SALE QUESTIONS
6 July 1992
BEAUFOUR-IPSEN SET ON INDEPENDENCE
6 July 1992
ROCHE'S HIVID GETS APPROVAL IN USA
29 June 1992
WELLCOME LOOKING TO OTC ZOVIRAX
29 June 1992
US FDA ABANDONS COMPANY ALERT LIST
29 June 1992
BARR AND FDA ON COLLISION COURSE
22 June 1992
FIRST EC LAUNCH OF DIDANOSINE
22 June 1992
EC DRUG INDUSTRY GETS PROACTIVE
15 June 1992
FDA INVESTIGATES AIDS DRUG CLAIMS
8 June 1992
VIDEX HEADING FOR JAPANESE APPROVAL
8 June 1992
GENERIC ZIDOVUDINE APPROVED IN CANADA
1 June 1992
COMBO AIDS THERAPY TESTED IN SPAIN
1 June 1992
BRAZIL STALLS ON PATENT REFORM
25 May 1992
ORTHODOX AIDS VIEW CHALLENGED
4 May 1992
RETROVIR TO VIDEX SWITCH BENEFIT
4 May 1992
RETROVIR & PATIENT SURVIVAL
27 April 1992
STOCK MARKET COMMENTARY: EUROPE
27 April 1992
LIMITED US APPROVAL RECOMMENDED FOR HIVID
27 April 1992
BULLETIN REViEWS EPOETIN
20 April 1992
TRIAL COULD BOOST VIDEX ACCEPTANCE
20 April 1992
STOCK MARKET COMMENTARY: EUROPE
20 April 1992
EFAs COULD REFORM ANTIVIRAL THERAPY
20 April 1992
"ROLLING" NDA FOR ADRIA'S RIFABUTIN
13 April 1992
UPJOHN UPDATES ON R&D PROGRESS
13 April 1992
VOLUME GROWTH FOR US DRUGMAKERS
9 March 1992
RETROVIR AND AIDS PATIENT SURVIVAL
9 March 1992
STOCK MARKET COMMENTARY: EUROPE
9 March 1992
HIV POPULATIONS "ARE STABILIZING"
17 February 1992
NEW CHEMICAL ENTITIES UPDATE FOR 1991
10 February 1992
STOCK MARKET COMMENTARY: EUROPE
10 February 1992
HIVID TRIAL SETBACK NOT SERIOUS, SAYS ROCHE
3 February 1992
"EXCELLENT START" TO 1992 AT WELLCOME
27 January 1992
REVISIONS FOR US ORPHAN DRUG ACT?
27 January 1992
ROCHE HALTS ZALCITABINE TRIAL
27 January 1992
AIDS MONOTHERAPIES COMPARED
20 January 1992
STUDY SHEDS LIGHT ON RETROVIR DOSE
13 January 1992
DRUG FIRMS ARE STOCK MARKET DARLINGS
13 January 1992
IMMUNEX COULD CAPTURE GM-CSF/IL-3 MARKET
6 January 1992
STOCK MARKET COMMENTARY: EUROPE
6 January 1992
ZOVIRAX/RETROVIR COMBO FOR AIDS?
6 January 1992
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
